GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » 3-Year EPS without NRI Growth Rate

MDXXF (Pharmala Biotech Holdings) 3-Year EPS without NRI Growth Rate : 30.70% (As of Nov. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings 3-Year EPS without NRI Growth Rate?

Pharmala Biotech Holdings's EPS without NRI for the three months ended in Nov. 2024 was $0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 30.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 4 years, the highest 3-Year average EPS without NRI Growth Rate of Pharmala Biotech Holdings was 30.70% per year. The lowest was 30.70% per year. And the median was 30.70% per year.


Competitive Comparison of Pharmala Biotech Holdings's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Pharmala Biotech Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's 3-Year EPS without NRI Growth Rate falls into.


;
;

Pharmala Biotech Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Pharmala Biotech Holdings  (OTCPK:MDXXF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Pharmala Biotech Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings Business Description

Traded in Other Exchanges
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.